DNDi invests in bringing all-new treatments through the research and development (R&D) pipeline – both by repurposing or modifying drugs from other therapeutic areas and by identifying and developing entirely new chemical entities.
We are committed to developing safe, effective, and affordable treatments for people with neglected diseases and neglected patients. Together with our partners, we are working on over 40 projects, including 20 projects focused on identifying or developing new chemical entities. We are also running over 25 clinical trials.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them.
Sleeping sickness
Transmitted by the bite of a tsetse fly and causes severe neurological disorders
We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease
Pediatric HIV
Without treatment, half of children die before their second birthday
We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response
Chagas disease
Causes heart and vital organ damage, after people are bitten by blood-sucking bugs
We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care
COVID-19
Devasting and deadly to many, there’s too little research to help the most vulnerable
We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners
Filaria: river blindness
Lead to unbearable itching, disfiguring skin lesions, and even blindness
We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease
Mycetoma
Often ends in amputation, after people get infected from stepping on a thorn
We’re conducting the world’s first trial for an alternative to current treatments, which are toxic and ineffective
Visceral leishmaniasis
One of the world’s biggest parasitic killers, spread by the bites of sandflies
We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects
Hepatitis C
Millions are left without treatment even though effective drugs exist
We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost
Cryptococcal meningitis
Without treatment, deadly for thousands of people with advanced HIV
We’re working to improve access to life-saving treatments and developing an easier-to-use formulation
Cutaneous leishmaniasis
Leaves disfiguring, life-long scars that lead to severe social stigma
We’re working to develop safer, shorter treatments for this disabling disease
Dengue
Rapidly spreading climate-sensitive disease with no specific treatment
We’re building a global partnership with dengue-endemic countries to develop a first treatment
Help neglected patients
DNDi’s generous supporters make sure we can take on the devastating diseases affecting the people who need our help the most.
Treatments delivered
Our teams have been working since 2003 to address gaps in the traditional biomedical R&D system that lead to serious unmet medical needs for neglected patients. Acting as a ‘conductor of a virtual orchestra’, DNDi collaborates with research partners around the world at all stages of the R&D process.
Together, we’ve discovered, developed, and delivered new treatments that reduce illness, suffering, and death from some of the world’s most neglected diseases. Discover more about the treatments we’ve delivered on our international website dndi.org.
TREATMENT DELIVERED
Fexinidazole for T.b. gambiense
An all-new, all-oral patient-friendly treatment. Approved by the European Medicines Agency in 2018, DNDi’s first ‘new chemical entity’ cures the most common form of sleeping sickness in just 10 days of simple, 1-pill-per-day treatment.
TREATMENT DELIVERED
4-in-1 (ABC/3TC/LPV/r)
A strawberry-flavoured, ‘4-in-1’ treatment for children. The 4-in-1 meets the treatment needs of the youngest children living with HIV. The combination of four antiretrovirals in easy-to-administer, heat-stable, strawberry-flavoured granules has been approved in South Africa.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
